Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01877811
Recruitment Status : Completed
First Posted : June 14, 2013
Last Update Posted : April 25, 2019
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This is a first-in-human, multicenter, open-label study consisting of 2 phases. Phase 1 is a dose escalation study of RXDX-105 (formerly known as CEP-32496) in patients with advanced solid tumors aimed at defining the recommended Phase 2 dose (RP2D) and schedule for administration. Phase 1b is a dose expansion in approximately 90 patients with advanced solid tumors with specific histologies and/or molecular alterations of interest. Patients in Phase 1b will be treated at the RP2D determined in Phase 1.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: RXDX-105 Phase 1

Detailed Description:

The primary objective of Phase 1 is to determine the recommended Phase 2 dose (RP2D) of RXDX-105. The primary objective of Phase 1b is to further assess the safety profile and tolerability of RXDX-105 at the RP2D The secondary objective is to evaluate the antitumor activity of RXDX-105 at the RP2D, as assessed by objective response rate (ORR) (complete response [CR] or partial response [PR]) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) in patients with advanced solid tumors with RET or BRAF mutations or rearrangements.

The RP2D has been determined and Phase 1 portion of the study is now closed to new patient enrollment.

Phase 1 b is open and enrolling patients with solid tumors harboring a RET rearrangement or mutation, or a BRAF rearrangement or mutation. Additionally, patients with Squamous NSCLC and lung adenocarcinomas with other alterations than RET or BRAF such as KRAS mutations, etc. will also be enrolled. Approximately 90 patients will be enrolled in Phase 1b.

Each phase of this study will consist of a 28-day screening period. Patients will be treated in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment. Patients in Phase 1 and 1b will be followed for 6 months after the last dose of study treatment.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 143 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Phase 1/1b, Single-Agent Study of RXDX-105 in Patients With Advanced Solid Tumors
Study Start Date : June 2013
Actual Primary Completion Date : December 2018
Actual Study Completion Date : February 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: RXDX-105 Drug: RXDX-105

During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.

During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment.

Other Name: CEP-32496, AC013773




Primary Outcome Measures :
  1. Phase 1: Dose Limiting Toxicities [ Time Frame: Approximately 12 months ]
    From signing of the informed consent up to approximately 12 months

  2. Phase 1: Occurrence of Adverse Events [ Time Frame: Approximately 12 months ]
    From signing of the informed consent up to approximately 12 months

  3. Phase 1b: Occurrence of Adverse Events [ Time Frame: Approximately 12 months ]
    To further assess the safety profile and tolerability of RXDX-105 at the RP2D


Secondary Outcome Measures :
  1. Phase 1: Maximum observed plasma drug concentration (Cmax) [ Time Frame: Day 1 to Day 16 ]
  2. Phase 1: Time of maximum observed plasma drug concentration (tmax) [ Time Frame: Day 1 to Day 16 ]
  3. Phase 1: Area under the plasma drug concentration versus time curve from time 0 to infinity (AUC0-∞) [ Time Frame: Day 1 to Day 16 ]
  4. Phase 1: Area under the plasma drug concentration versus time curve from time 0 to the last measureable drug concentration (AUC0-t) [ Time Frame: Day 1 to Day 16 ]
  5. Phase 1: Area under the plasma drug concentration versus time curve from time 0 to 24 hours after study drug administration (AUC0-24) [ Time Frame: Day 1 to Day 16 ]
  6. Phase 1: Terminal elimination rate constant (λz) [ Time Frame: Day 1 to Day 16 ]
  7. Phase 1: Terminal elimination half-life (t1/2) [ Time Frame: Day 1 to Day 16 ]
  8. Phase 1: Apparent clearance of study drug from plasma (CL/F) [ Time Frame: Day 1 to Day 16 ]
  9. Phase 1b: Objective Response Rate [ Time Frame: Approximately 12 months ]
    Objective response rate is defined as the proportion of patients with advanced solid tumors achieving best overall response of complete response (CR), or partial response (PR), as assessed using RECIST v1.1

  10. Phase 1b: Duration of Objective Response [ Time Frame: Approximately 12 months ]
    The duration of objective response is defined as the time interval from the date of first documented response (CR or PR) to disease progression or death, whichever occurs first

  11. Phase 1b: Clinical Benefit Rate [ Time Frame: Approximately 12 months ]
    Clinical benefit rate is defined as the proportion of patients achieving a complete response (CR), partial response (PR) or stable disease (SD) for 6 months



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria for Phase 1b:

  1. Patients must have histologically or cytologically confirmed advanced solid tumors with a histology and/or molecular alteration of interest as defined in Section 4, detected by a CLIA-certified or equivalently accredited diagnostic laboratory

    • Squamous NSCLC and Non-squamous NSCLC (no known RET alterations or BRAF V600E mutations) patients must have archival tissue available for analysis by Ignyta; all other patients must send tissue to Ignyta, if tissue is available

  2. Prior Treatment:

    • Patients with BRAF V600E mutations must be TKI-naïve; any number of other prior therapies are allowed
    • NSCLC patients with RET alterations who have had a prior RET inhibitor or are RET inhibitor-naïve will be enrolled; (any number of other prior therapies are allowed); all other histologies with RET alterations must be RET inhibitor-naïve
    • Patients with Squamous NSCLC and Non-squamous NSCLC (no known RET alterations or BRAF V600E mutations) may have had prior TKIs and any number of other prior therapies
  3. Measurable disease according to RECIST v1.1 for all patients except patients with RET altered tumors; patients with RET altered tumors must have evaluable disease, but are not required to have measurable disease
  4. Patients with treated, stable CNS metastases, including leptomeningeal carcinomatosis are allowed. The use of seizure prophylaxis is allowed. Patients requiring steroids must be at a stable or decreasing dose for at least 2 weeks prior to the start of RXDX-105 treatment.
  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  6. Able to ingest oral medication
  7. Other inclusion criteria apply

Exclusion Criteria for Phase 1b:

  1. Treated with systemic anticancer therapy or an investigational agent within 2 weeks or 5 half-lives, whichever is shorter, prior to start of study drug treatment (4 weeks for antibody therapy and immunotherapy, and 2 weeks for bevacizumab in colon cancer patients)
  2. Major surgery 21 days or less prior to starting study drug or has not recovered from adverse effects of such therapy
  3. Radiotherapy within 2 weeks prior to start of study drug treatment (palliative radiation or stereotactic radiosurgery within 7 days prior to start of study treatment). Patients must have recovered from all radiotherapy-related toxicities
  4. History of non-pharmacologically induced prolonged QTc interval (e.g., repeated demonstration of a QTc interval > 500 milliseconds from ECGs performed at least 24 hours apart)
  5. Major active infection requiring parenteral antibiotics
  6. Severe or unstable medical condition, such as congestive heart failure (New York Heart Association [NYHA] Class III or IV), ischemic heart disease, uncontrolled hypertension, uncontrolled diabetes mellitus, psychiatric condition, as well as an uncontrolled cardiac arrhythmia requiring medication (≥ Grade 2, according to NCI CTCAE v4.03), myocardial infarction within 6 months prior to starting study treatment, or any other significant or unstable concurrent medical illness that in the opinion of the Investigator would preclude protocol therapy
  7. History of other previous cancer that would interfere with the determination of safety or efficacy of RXDX-105 with respect to the qualifying solid tumor malignancy
  8. Known infection with human immunodeficiency virus (HIV) and active hepatitis B or hepatitis C
  9. Current participation in another clinical study of an investigational agent, vaccine, or device. Concomitant participation in observational studies is acceptable
  10. Presence of a significant gastrointestinal disorder that, in the opinion of the Investigator or Sponsor, could interfere with absorption of RXDX-105 (e.g., malabsorption syndrome, gastrointestinal surgery)
  11. Known hypersensitivity to any of the components of RXDX-105

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01877811


Locations
Layout table for location information
United States, California
City of Hope
Duarte, California, United States
University of California Irvine College of Medicine
Irvine, California, United States
University of California San Diego Moores Cancer Center
San Diego, California, United States
United States, District of Columbia
Lombardi Comprehensive Cancer Center, Georgetown
Washington, District of Columbia, United States
United States, Florida
Florida Cancer Center
Sarasota, Florida, United States
United States, Georgia
University Cancer & Blood Center, LLC
Athens, Georgia, United States
United States, Massachusetts
Massachusetts General Hospital/Beth Israel Deaconess Med. Ctr./Dana Farber Cancer Institute
Boston, Massachusetts, United States
United States, Michigan
Henry Ford Health System
Detroit, Michigan, United States
Karmanos Cancer Center
Detroit, Michigan, United States
United States, Missouri
Washington University
Saint Louis, Missouri, United States
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
United States, Washington
University of Washington, Seattle Cancer Care Alliance
Seattle, Washington, United States
Sponsors and Collaborators
Hoffmann-La Roche

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01877811     History of Changes
Other Study ID Numbers: RXDX-105-01
First Posted: June 14, 2013    Key Record Dates
Last Update Posted: April 25, 2019
Last Verified: April 2019

Keywords provided by Hoffmann-La Roche:
Lung Cancer
RET Inhibitor
Solid Tumors
RET mutations or rearrangements
BRAF mutations or rearrangements
Squamous NSCLC
KRAS mutation
Other Lung adenocarcinomas